HighTower Advisors LLC Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HighTower Advisors LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,302 shares of the biopharmaceutical company’s stock after selling 2,723 shares during the period. HighTower Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $21,585,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AGF Management Ltd. increased its stake in Regeneron Pharmaceuticals by 281.2% during the 4th quarter. AGF Management Ltd. now owns 1,277 shares of the biopharmaceutical company’s stock worth $910,000 after buying an additional 942 shares in the last quarter. Wealthfront Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 68.5% during the 4th quarter. Wealthfront Advisers LLC now owns 15,990 shares of the biopharmaceutical company’s stock worth $11,390,000 after purchasing an additional 6,501 shares during the last quarter. Cornerstone Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 31.7% during the 4th quarter. Cornerstone Advisors LLC now owns 7,900 shares of the biopharmaceutical company’s stock worth $5,627,000 after purchasing an additional 1,900 shares during the last quarter. Mcdonald Capital Investors Inc. CA boosted its holdings in shares of Regeneron Pharmaceuticals by 24.7% during the 4th quarter. Mcdonald Capital Investors Inc. CA now owns 170,180 shares of the biopharmaceutical company’s stock worth $121,224,000 after purchasing an additional 33,727 shares during the last quarter. Finally, Independent Advisor Alliance boosted its holdings in shares of Regeneron Pharmaceuticals by 117.3% during the 4th quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company’s stock worth $340,000 after purchasing an additional 258 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. TD Cowen decreased their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Down 2.0 %

Regeneron Pharmaceuticals stock opened at $666.87 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock’s fifty day simple moving average is $694.91 and its 200-day simple moving average is $833.75. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $72.91 billion, a P/E ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.